Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hypoxia-inducible factor 1-alpha (HIF-1α) promoter G-quadruplex DNA is a non-canonical secondary nucleic acid structure formed within a guanine-rich polypurine/polypyrimidine tract of the HIF1A gene promoter [1, 4]. Located typically between positions -65 and -85 relative to the transcription start site, this G-quadruplex (G4) acts as a critical regulatory element or molecular switch for gene expression [2, 3]. Under both normoxic and hypoxic conditions, the formation and stability of this structure can modulate the binding of transcription factors, such as AP2, and the progression of the transcription machinery [5]. In many solid tumors, HIF-1α is constitutively overexpressed or induced by hypoxia, driving key oncogenic processes including angiogenesis, metabolic reprogramming toward glycolysis, and tumor cell survival [6, 8]. Small molecule ligands, such as CL67, TmPyP4, and telomestatin, have been shown to bind and stabilize the HIF-1α G-quadruplex, leading to the repression of HIF-1α transcription and the subsequent downregulation of its downstream targets like VEGF [1, 4, 6]. Consequently, this DNA structure represents a promising therapeutic target for cancer treatment, offering a way to inhibit the HIF pathway independently of traditional oxygen-dependent degradation mechanisms [1, 10].
Stabilization of the G-quadruplex structure within the gene promoter to sterically hinder the transcription machinery and block transcription factor binding, thereby inhibiting gene transcription and subsequent protein expression [1, 5, 6].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxia-inducible factor 1-alpha promoter G-quadruplex DNA (HIF-1α promoter G4 DNA).